April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds
March 2nd 2019Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
Read More
Palliative Care, Hospice Improves End-of-Life Care Among Patients With Hematologic Malignancies
February 23rd 2019Patients with hematologic malignancies often receive intensive care at the end of life (EOL), but new research has demonstrated that hospice services and palliative care are associated with significantly improved EOL care quality.
Read More
Preparing Patients and the Health System for Curative Therapies in the Pipeline
February 12th 2019Experts at the “Paying for Cures: Ensuring patient access and system sustainability" event discussed how the healthcare system can pay for curative therapies that have high upfront costs with benefits that accrue over time.
Read More
Identifying Patient Preferences in MM Treatment Improves Shared Decision Making
February 10th 2019Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.
Read More
Ineligibility for Intensive Chemotherapy Impacts QoL Scores, Survival in AML
February 7th 2019Patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy tend to have poor health-related quality of life (HRQoL) scores that are independent predictors of poor survival, a recent study reported.
Read More
Long Noncoding RNAs Contribute to Prominent Signaling Pathways in BCP-ALL
February 2nd 2019Long noncoding RNAs (lncRNAs) are involved in the pathogenesis of b-cell precursor acute lymphoblastic leukemia (BCP-ALL) and contribute to the stratification of BCP-ALL subtypes, according to results from a recent study.
Read More
Once-Weekly Carfilzomib Improves PFS, OS in High-Risk Patients With MM Over Twice-Weekly Dose
January 19th 2019Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.
Read More
Maintenance Therapy for Multiple Myeloma Needs Improvement Beyond Lenalidomide, Study Says
January 12th 2019Maintenance therapy with lenalidomide remains a standard of care for patients with multiple myeloma. However, optimizing maintenance therapy in this setting is required as a result of lenalidomide’s lack of overall survival benefit and improvement in outcomes for patients with high-risk cytogenic abnormalities, according to a recent study.
Read More
Dr Brian Koffman: It Is Critical That Patients Educate Themselves and Leverage Their Advantages
January 5th 2019As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.
Watch
Radiotherapy Plus Chemotherapy Improves Survival in Pediatric Patients With Hodgkin Lymphoma
January 5th 2019Pediatric patients with early-stage Hodgkin lymphoma who are treated with chemotherapy followed by radiotherapy, known as combined modality therapy, have an improved 5-year survival rate compared with patients treated with chemotherapy alone.
Read More
Childhood Hodgkin Lymphoma Survivors Have Increased Risk of Later Tumors
December 29th 2018Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.
Read More
Dr Alison Moskowitz Discusses Survival Disparities in Hodgkin Lymphoma
December 29th 2018Patients who are over 60 with Hodgkin lymphoma have much lower survival rates than patients who are under 60, explained Alison J. Moskowitz, MD, medical oncologist, clinical director, lymphoma inpatient unit, Memorial Sloan Kettering Cancer Center.
Watch
Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS
December 28th 2018Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemotherapy regimens, according to a new study in JAMA Oncology.
Read More
Dr Brian Koffman Highlights Incredible Responses to CLL Treatments
December 20th 2018There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Watch
Diabetes, Cancer Interviews Among Most-Watched Videos of 2018
December 20th 2018Throughout the year, The American Journal of Managed Care® (AJMC®) offered a number of video programs, including Peer Exchange discussions and interviews, on a range of topics. Here are the most-watched videos published by AJMC® in 2018.
Read More
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 19th 2018During the 60th American Society of Hematology Annual Meeting & Exposition held December 1-4 in San Diego, California, Norman Sharpless, MD, director, National Cancer Institute (NCI), brought attention to several advances made in hematologic malignancies over the past year and highlighted 4 areas of focus going forward.
Read More
Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation
December 12th 2018Following failure with ruxolitinib, there are limited treatment options available and among these patients who fail on the treatment, prognosis is unfavorable, particularly among those who started ruxolitinib with advanced stage disease, according to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition.
Read More
ELOQUENT-3: Adding Elotuzumab to Pomalidomide, Dexamethasone Improves PFS in R/R Multiple Myeloma
December 8th 2018ELOQUENT-3 trial results found that adding elotuzumab to pomalidomide and dexamethasone improved progression-free survival (PFS) and overall response rate in patients with multiple myeloma that had relapsed from or were refractory to (R/R) lenalidomide and a proteasome inhibitor.
Read More
Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis
December 7th 2018According to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition, held December 1-4 in San Diego, California, a World Health Organization–defined diagnosis of primary myelofibrosis may help better identify patients who may need strict monitoring during treatment with ruxolitinib.
Read More